Furthermore, the reactivity of platelets obtained from dabigatran-treated mice was diminished both at 24 h as well as on the 7th day after i.v. injection of 4T1 breast cancer cells, as evidenced by diminished expression of the active form of GPIIb/IIIa in dabigatran-treated mice compared with non-treated mice in response to thrombin (.025 U ml−1) (Figures 5D–F), directly supporting the inhibitory effects of dabigatran treatment in vivo on thrombin-dependent platelet activation. Here, ITGA2B is linked to breast carcinoma.